BSH 2019 | Daunorubicin and cytarabine approved for AML treatment within NHS Scotland

Zack Pemberton-Whiteley

Daunorubicin and cytarabine were both recently approved by SMC for the treatment of AML within NHS Scotland. Zack Pemberton-Whiteley, Leukaemia Care, Worcester, UK, discusses this at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.

Share this video